Literature DB >> 11755440

Epidemiology of clinically diagnosed community-acquired pneumonia in the primary care setting: results from the 1999-2000 respiratory surveillance program.

M H Gotfried1.   

Abstract

To evaluate the prevalence of typical pathogens, level of resistance, and risk factors associated with community-acquired pneumonia (CAP) in the outpatient primary care setting and define current antibiotic treatment for office-based CAP, the Respiratory Surveillance Program (RESP) recruited 1,200 primary care clinics during the 1999-2000 respiratory infection season. Participating community-based physicians submitted sputum samples from patients presenting with a community-acquired respiratory infection including community-acquired pneumonia (CAP). All patients were aged > or =18 years. Patient demographics and risk factors were collected. Physicians express-mailed the specimens to a central laboratory for identification and susceptibility testing. All isolates were tested against a select panel of antimicrobial agents that are used to treat CAP. Patients with CAP were diagnosed by the treating physicians. Chest radiographs were not required as part of the study. A total of 610 specimens were submitted from patients with CAP. A smoking history or reported history of chronic obstructive pulmonary disease were present in >50% of those diagnosed with CAP. The most common pathogens were, in order of prevalence, Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis. During the study period, a variety of antibiotics were prescribed for the treatment of outpatient CAP. The top 3 prescribed antibiotics include levofloxacin (23%), clarithromycin (19%), and azithromycin (10%). Gatifloxacin, which was approved in December 1999 and therefore available for only part of the study, accounted for 4% of the prescriptions. Of S pneumoniae isolates, 8% demonstrated high-level resistance to penicillin (> or =2 microg/mL) and 33% were found resistant to macrolides and trimethoprim/sulfamethoxazole. All S pneumoniae isolates were sensitive to gatifloxacin, vancomycin, and levofloxacin. Other less common organisms isolated were staphylococci, streptococci, Enterobacteriaceae, Pseudomonas spp, and Acinetobacter spp. The choice of antibiotic to treat outpatient CAP varies from practice to practice and does not appear to be influenced by the patient's age, the patient's history of smoking, or comorbidity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11755440     DOI: 10.1016/s0002-9343(01)01028-2

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  8 in total

1.  Analysis of genetic relatedness of Haemophilus influenzae isolates by multilocus sequence typing.

Authors:  Alice L Erwin; Sara A Sandstedt; Paul J Bonthuis; Jennifer L Geelhood; Kevin L Nelson; William C T Unrath; Mathew A Diggle; Mary J Theodore; Cynthia R Pleatman; Elizabeth A Mothershed; Claudio T Sacchi; Leonard W Mayer; Janet R Gilsdorf; Arnold L Smith
Journal:  J Bacteriol       Date:  2007-12-07       Impact factor: 3.490

2.  Role of the AcrAB-TolC efflux pump in determining susceptibility of Haemophilus influenzae to the novel peptide deformylase inhibitor LBM415.

Authors:  Charles R Dean; Shubha Narayan; Denis M Daigle; JoAnn L Dzink-Fox; Xiaoling Puyang; Kathryn R Bracken; Karl E Dean; Beat Weidmann; Zhengyu Yuan; Rakesh Jain; Neil S Ryder
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  Community-acquired pneumonia in Shanghai, China: microbial etiology and implications for empirical therapy in a prospective study of 389 patients.

Authors:  H H Huang; Y Y Zhang; Q Y Xiu; X Zhou; S G Huang; Q Lu; D M Wang; F Wang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-06       Impact factor: 3.267

4.  Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates.

Authors:  Mihaela Peric; Bülent Bozdogan; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

5.  The influence of comorbidity on the effect of levofloxacin treatment success of ambulatory respiratory tract infections.

Authors:  Heinz Burgmann; Bernd Mayer; Arno Lukas; Friedrich Kumbein; Rainer Oberbauer
Journal:  Wien Med Wochenschr       Date:  2003

6.  The determinants of the antibiotic resistance process.

Authors:  Beatriz Espinosa Franco; Marina Altagracia Martínez; Martha A Sánchez Rodríguez; Albert I Wertheimer
Journal:  Infect Drug Resist       Date:  2009-04-17       Impact factor: 4.003

Review 7.  A review of the role of Haemophilus influenzae in community-acquired pneumonia.

Authors:  Mary P E Slack
Journal:  Pneumonia (Nathan)       Date:  2015-12-01

Review 8.  Guide to selection of fluoroquinolones in patients with lower respiratory tract infections.

Authors:  Wael E Shams; Martin E Evans
Journal:  Drugs       Date:  2005       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.